EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C15H19N5O.C7H8O3S |
| Net Charge | 0 |
| Average Mass | 457.556 |
| Monoisotopic Mass | 457.17838 |
| SMILES | C=CC(=O)N1C[C@H](Nc2ncnc3nccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1 |
| InChI | InChI=1S/C15H19N5O.C7H8O3S/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15;1-6-2-4-7(5-3-6)11(8,9)10/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19);2-5H,1H3,(H,8,9,10)/t10-,11+;/m0./s1 |
| InChIKey | YOZLVAFWYLSRRN-VZXYPILPSA-N |
| Roles Classification |
|---|
| Biological Roles: | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that specifically blocks the action of non-specific protein-tyrosine kinase (EC 2.7.10.2). immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. |
| Applications: | dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. anti-inflammatory drug A substance that reduces or suppresses inflammation. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antirheumatic drug A drug used to treat rheumatoid arthritis. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| ritlecitinib tosylate (CHEBI:229234) has part ritlecitinib(1+) (CHEBI:229235) |
| ritlecitinib tosylate (CHEBI:229234) has role anti-inflammatory drug (CHEBI:35472) |
| ritlecitinib tosylate (CHEBI:229234) has role antirheumatic drug (CHEBI:35842) |
| ritlecitinib tosylate (CHEBI:229234) has role dermatologic drug (CHEBI:50177) |
| ritlecitinib tosylate (CHEBI:229234) has role EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor (CHEBI:76617) |
| ritlecitinib tosylate (CHEBI:229234) has role immunosuppressive agent (CHEBI:35705) |
| ritlecitinib tosylate (CHEBI:229234) is a organosulfonate salt (CHEBI:64382) |
| IUPAC Name |
|---|
| 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one 4-methylbenzenesulfonate (1:1) |
| Synonyms | Source |
|---|---|
| ritlecitinib tosilate | KEGG DRUG |
| PF-06651600 tosylate | DrugBank |
| 1-{(2S,5R)-2-methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one 4 methylbenzene-1-sulfonic acid | ChEBI |
| 4-methylbenzene-1-sulfonic acid—1-{(2S,5R)-2-methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one (1/1) | IUPAC |
| Brand Name | Source |
|---|---|
| Litfulo | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| D11970 | KEGG DRUG |
| DBSALT003482 | DrugBank |
| Registry Numbers | Sources |
|---|---|
| CAS:2192215-81-7 | KEGG DRUG |
| Citations |
|---|